Skip to main content

Stanford’s Laboratory for Cell and Gene Medicine aims to ‘cure the incurable’

laboratory for cell gene medicine braincancer
Creative Commons
When you read about initiatives like Stanford University’s new Laboratory for Cell and Gene Medicine, it’s difficult to think of too many other places on Earth where more exciting — and potentially life-changing — work is being done.

Opened in September, the 25,000-square-foot facility is currently attacking a number of the world’s most challenging medical problems. As laboratory director Dr. David DiGiusto puts it, it’s all about “curing the incurable.”

“Many diseases cannot be cured with conventional therapies that are palliative only in nature,” laboratory director DiGiusto told Digital Trends. “Other diseases have no effective treatments at all. Our mission is to develop and test cures for incurable diseases using cell and gene therapy. We are currently working on cancer, monogenic disease (i.e., SCID, sickle cell, and other immune deficiencies), and regenerative medicine [like] dermatology, neurosciences, and cardiovascular medicine.”

The lab is currently carrying out a range of exciting projects in its “clean rooms.” These include sheets of genetically corrected skin that can be given as skin grafts to patients suffering from the blistering skin disease epidermolysis bullosa, in which layers of skin don’t adhere properly to the body. There are also projects to regenerate corneal cells in the eye, repair mutations in blood cells, genetically engineer immune system T cells to fight cancer, and more.

As DiGiusto points out, these efforts have the possibility to “end great suffering if ultimately successfully commercialized.”

While there are other laboratories around the U.S. working on projects like cell-based approaches to cancer, what is impressive about Stanford’s efforts is the massive scale. A bit like legendary research facilities such as Xerox PARC — where much of the technology behind the personal computer revolution was invented — there are so many interesting projects being carried out at the Laboratory for Cell and Gene Medicine that it’s difficult to name them all.

Suffice it to say that if you hadn’t heard of the lab before now, that will almost certainly change over the coming years.

“There are now quite a few academic manufacturing facilities supporting [similar] efforts but most are working on only two or three products,” DiGiusto said. “Stanford has a broad portfolio of candidate cell and gene therapies that we will likely have eight to 10 products in the queue at all times. Because Stanford has the basic science, translational, and manufacturing capability, and 2 hospitals focused on clinical research — Stanford Health Care and Lucile Packard Children’s Hospital — we have a tremendous infrastructure in place to develop and test a wide array of candidate therapies. The magnitude of the effort is quite significant.”

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Expensive gene therapy receives its first patient in a commercial treatment

A patient with an extremely rare immune disease has been treated with commercial gene therapy for the first time, GlaxoSmithKline, the company behind the therapy, told MIT Technology Review on Tuesday. The treatment come almost a year after the therapy was approved for sale in Europe.

Known as Strimvelis, the therapy treats a rare inherited immune deficiency by fixing a problem within the patient’s DNA.

Read more
Animal gene sequencing project aims to assemble a comprehensive genomic zoo
genome10k sequencing endangered species 15161284 l

You’ve quite possibly heard of the Human Genome Project, the massive international science research project dedicated to sequencing the human DNA. A less well-known project called Genome 10K has a not-unrelated mission -- but instead of mapping just the human genome, it’s dedicated to sequencing the genome of thousands of animal species, including those most at risk of extinction.

“The purpose of the Genome 10K project is to assemble a genomic zoo of DNA sequences representing the full diversity of vertebrate animals, including at least 10,000 different vertebrate species,” David Haussler, the Genome 10K trustee and scientific director at the University of California Santa Cruz Genomics Institute, told Digital Trends. “Establishing the genetic diversity of vertebrate species would create a priceless resource for the life sciences and worldwide conservation efforts. We have only just begun to understand our natural environment. Because virtually all the biology of an animal is encoded in its genome, the Genome 10K project will provide a great leap forward.”

Read more
Programmable cells may be the next step toward making us real-life cyborgs
programmable cells cyborg 26790923 l

With high-tech implants, mind-controlled prostheses, and even head-up displays like Google Glass, it’s pretty clear that the cyborg dream of machine-augmented humans is no longer limited to science fiction.

Researchers from the University of Maryland have taken that dream to the next level, courtesy of new research showing how the “gene expression” of biological cells can be controlled electronically and even "programmed" to behave in different ways.

Read more